This study investigates genotype-guided dosing in patients with pancreas cancer and colorectal cancer. It focuses on individuals who are UGT1A1 intermediate metabolizers or usual UGT metabolizers.
The study evaluates the effectiveness of using genotype information to guide dosing compared to usual care. It looks at how this approach impacts treatment outcomes for the participants.
- Who can participate: Adults aged 18 and older with stage I-IV pancreas cancer or stage III-IV colorectal cancer, having adequate organ and marrow function and a performance status of 1 or less, are eligible.
- Study details: Participants will be assigned to either genotype-guided dosing or usual care.